Related Experiment Video

Updated: Apr 24, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K

Mycophenolate mofetil to treat neuromyelitis optica: is it time for a randomized trial?

Bruce Cree1

  • 1Department of Neurology, Multiple Sclerosis Center, University of California San Francisco.

JAMA Neurology
|September 10, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice

Published on: April 15, 2014

83.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

15.9K

Related Experiment Videos

Last Updated: Apr 24, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

12.1K
Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice

Published on: April 15, 2014

83.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

15.9K

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K

Articles linked to this work by shared authors, journal, and citation graph.

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

medRxiv : the preprint server for health sciences·2026

Update on novel multiple sclerosis treatments: from dismal defeat to scintillating success.

Current opinion in neurology·2025

Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study.

NPJ digital medicine·2020

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.

BMC neurology·2014

Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica.

Archives of neurology·2010

Neuromyelitis optica: diagnosis, pathogenesis, and treatment.

Current neurology and neuroscience reports·2008

Lifelong De Novo Aneurysm Risk After Aneurysmal Subarachnoid Hemorrhage in Young Survivors.

JAMA neurology·2026

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

JAMA neurology·2026

Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy.

JAMA neurology·2026

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

JAMA neurology·2026

Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial.

JAMA neurology·2026

Plasma Biomarkers for Neocortical Tau Burden.

JAMA neurology·2026

[Chronic-phase chronic myeloid leukemia complicated by dasatinib-associated lymphadenopathy].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Comparison of clinical characteristics and cytogenetic abnormalities between myelodysplastic syndromes in Nagasaki atomic bomb survivors and therapy-related myelodysplastic syndromes].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

Low-Dose Antifungal Therapy Improves Sputum Rheology and Symptoms in Fungus-Associated Chronic Cough.

Medical mycology journal·2026

Nomenclatural Changes of Fungal Pathogens Causing Dermatomycoses.

Medical mycology journal·2026

Association Between Iron Metabolism and Microalbuminuria in Patients With Type 2 Diabetes Mellitus and MASLD.

International journal of endocrinology·2026

Cultivation and preliminary chemical analyses of the sclerotium-forming, termite fungus garden-associated Xylaria minima.

MycoKeys·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us